Back to today’s briefing

Story perspectives

Metformin Cuts Skin Cancer Risk by Up to 67%

1/16/2025

36 8

Summary

Story summary

A groundbreaking study in the Journal of Drugs in Dermatology reveals that metformin, commonly used for diabetes, could significantly reduce the risk of skin cancers like basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Patients taking metformin showed a remarkable 67% lower chance of developing BCC and 55% for SCC, though the benefits were less pronounced for Black patients. More research is essential to explore these findings.

1 of 1

Story summary

A groundbreaking study in the Journal of Drugs in Dermatology reveals that metformin, commonly used for diabetes, could significantly reduce the risk of skin cancers like basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Patients taking metformin showed a remarkable 67% lower chance of developing BCC and 55% for SCC, though the benefits were less pronounced for Black patients. More research is essential to explore these findings.